UNICA IRIS Institutional Research Information System

PUZZONI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 60.192
NA - Nord America 3.451
AS - Asia 1.953
SA - Sud America 300
AF - Africa 53
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 65.953
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59.359
US - Stati Uniti d'America 3.361
SG - Singapore 860
CN - Cina 521
BR - Brasile 223
VN - Vietnam 222
SE - Svezia 205
DE - Germania 123
FR - Francia 99
FI - Finlandia 82
GB - Regno Unito 80
HK - Hong Kong 70
IN - India 67
UA - Ucraina 66
CA - Canada 57
NL - Olanda 48
BD - Bangladesh 30
KR - Corea 24
MX - Messico 23
AR - Argentina 21
JP - Giappone 21
PL - Polonia 21
AT - Austria 20
IQ - Iraq 20
ES - Italia 18
TR - Turchia 18
ZA - Sudafrica 17
EC - Ecuador 16
CO - Colombia 15
ID - Indonesia 14
PK - Pakistan 14
IE - Irlanda 13
VE - Venezuela 12
MA - Marocco 11
RU - Federazione Russa 11
BE - Belgio 9
PH - Filippine 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
KG - Kirghizistan 7
UZ - Uzbekistan 7
SA - Arabia Saudita 6
TN - Tunisia 6
IL - Israele 5
TH - Thailandia 5
CL - Cile 4
CZ - Repubblica Ceca 4
EG - Egitto 4
KE - Kenya 4
MK - Macedonia 4
PE - Perù 4
AU - Australia 3
GR - Grecia 3
LT - Lituania 3
LV - Lettonia 3
NP - Nepal 3
PY - Paraguay 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
DZ - Algeria 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
SV - El Salvador 2
BB - Barbados 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MN - Mongolia 1
MT - Malta 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 65.951
Salva come PNG Salva come JPEG
Città #
Cagliari 57.461
Uta 1.551
Singapore 507
Ashburn 394
Dallas 296
San Jose 258
Fairfield 245
Boardman 149
Woodbridge 133
Nyköping 129
Houston 127
Seattle 112
Beijing 111
Chandler 111
Los Angeles 93
Cambridge 87
Wilmington 77
Council Bluffs 71
Dearborn 69
Ho Chi Minh City 66
New York 66
Hong Kong 62
Santa Clara 62
Helsinki 56
The Dalles 53
Ann Arbor 51
Hanoi 42
Rome 42
Shanghai 39
Lauterbourg 38
Boston 37
Orem 31
Jacksonville 30
Dong Ket 28
Buffalo 27
Amsterdam 26
Chicago 26
Frankfurt am Main 25
Hefei 25
Munich 25
São Paulo 25
Nanjing 23
Seoul 23
London 21
Redondo Beach 19
San Diego 19
Guangzhou 18
Nuremberg 18
Toronto 17
Warsaw 17
Milan 15
Montreal 15
Paris 15
Pune 14
Phoenix 13
Shenyang 13
Tokyo 13
Atlanta 12
Düsseldorf 12
Hangzhou 12
Turku 12
Chennai 11
Poplar 11
Zhengzhou 11
Dublin 10
Brooklyn 9
Stockholm 9
Tianjin 9
Vienna 9
Changsha 8
Da Nang 8
Haiphong 8
Mont-saint-hilaire 8
Naples 8
Rio de Janeiro 8
Shenzhen 8
Wuhan 8
Augusta 7
Baghdad 7
Bishkek 7
Casablanca 7
Columbus 7
Jiaxing 7
Johannesburg 7
Medellín 7
Mumbai 7
Tashkent 7
Belo Horizonte 6
Biên Hòa 6
Buenos Aires 6
Charlotte 6
Denver 6
Hải Dương 6
Nanchang 6
New Delhi 6
Quito 6
Redwood City 6
Salt Lake City 6
Selargius 6
Bexley 5
Totale 63.474
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.182
Clustered protocadherins methylation alterations in cancer 3.331
BRAF-mutant colorectal cancer, a different breed evolving 3.246
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.983
Molecular-biology-driven treatment for metastatic colorectal cancer 2.773
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.702
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.642
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.456
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.376
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.339
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.145
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.126
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.979
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.695
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.637
Immunotherapy and Cancer: The Multi-Omics Perspective 1.619
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.547
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.419
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.365
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.345
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.299
Immunotherapy for colorectal cancer: where are we heading? 1.277
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.271
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.224
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.096
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.088
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 1.016
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 997
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 964
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 963
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 862
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 777
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 756
Uncovering key targets of success for immunotherapy in pancreatic cancer 728
Cholangiocarcinoma: new perspectives for new horizons 727
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 606
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 510
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 441
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-RAS and N-RAS wild type metastatic colorectal cancer (SUPER-PEAK) 351
CD44: A New Prognostic Marker in Colorectal Cancer? 276
A new prognostic score for biliary tract cancer: a multicenter experience 225
REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol) 223
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 218
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 208
Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment 205
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 190
Medical management of malignant bowel obstruction: our center experience 184
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 181
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 176
LONG-TERM RESPONSE TO SUNITINIB, EVEROLIMUS AND AXITINIB SEQUENTIALLY USED IN A YOUNG WOMEN WITH MRCC. A CASE REPORT 149
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 136
Preoperatory FLOT Regimen for Gastroesophageal Cancer and Renal Function: A New Onco-Nephrological Perspective 127
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 122
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 119
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 115
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 114
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 108
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 107
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 103
Totale 66.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.962
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.962
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021506 0 0 0 0 0 0 0 0 0 0 0 506
2021/20223.263 341 193 156 245 212 210 192 221 297 365 335 496
2022/20235.508 509 934 730 402 390 440 230 413 343 500 378 239
2023/20247.333 338 205 187 345 509 854 854 2.301 271 372 562 535
2024/202514.465 4.177 4.456 1.416 1.341 691 965 752 66 159 132 110 200
2025/20265.029 382 281 470 432 376 357 1.055 447 310 469 286 164
Totale 66.146